蒂尔泽帕提德和肥胖症的运动训练
Behnam Bagherzadeh-Rahmani1, Emanuele Marzetti2,3, Esmail Karami4
1Department of Exercise Physiology, Faculty of Sport Sciences, Hakim Sabzevari University, Sabzevar, Iran.
Clinical hemorheology and microcirculation
|April 19, 2024
概括
耐力和有氧训练 (RT+AT) 单独改善了肥胖士兵的健康状况和胰岛素耐药性,而不是与蒂尔泽帕蒂德结合使用. 当与运动一起使用时,蒂尔泽帕提德补充剂没有提供额外的益处.
科学领域:
- 运动生理学 运动生理学
- 代谢健康 代谢健康
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖和糖尿病前期症对健康构成重大挑战,特别是在军事人口中.
- 研究了联合炼方式和药理干预措施,以改善代谢健康.
- 蒂尔泽帕提德是一种用于管理代谢状况的新型治疗剂.
研究的目的:
- 为了研究6周的联合抵抗训练 (RT) 和有氧训练 (AT) 与提尔泽帕提德补充剂对糖尿病前肥胖士兵的脂质特征,胰岛素耐药性,人体特征和身体健康的影响.
- 为了比较单独运动的疗效与与蒂尔泽帕提德联合运动的疗效.
- 为了评估不同剂量的提尔泽帕提德与运动结合.
主要方法:
- 61名肥胖男性被随机分为六组:安慰剂,提尔泽帕提德 (5mg或2.5mg) 或运动与安慰剂,提尔泽帕提德5mg或提尔泽帕提德2.5mg相结合.
- 运动干预包括6周的RT与AT相结合,每周3次.
- 评估包括人体测量,身体组成,心肺健康 (VO2max),肌肉强度 (1RM) 和血液生物化学 (脂质,葡萄糖,胰岛素,HOMA-IR).
主要成果:
- 与控制组相比,与安慰剂或提尔泽帕提德联合炼显著降低了体重,BMI,腰围,脂肪量,禁食血糖,LDL-C,总胆固醇,甘油三和HOMA-IR.
- HDL-C,胸部压力和腿部压力强度随着运动干预显著增加.
- 与安慰剂和蒂尔泽帕提德组相比,仅运动组的VO2max显著增加,胰岛素水平显著降低.
结论:
- 在糖尿病前肥胖士兵中,单独服用六周的联合RT + AT比与提尔泽帕提德相结合更有效地改善心肺健康,力量和胰岛素调节.
- 当与运动训练相结合时,5mg或2.5mg的提尔泽帕提德补充剂没有提供显著的额外益处.
- 当与运动一起使用时,两种蒂尔泽帕提德剂量之间的结果没有显著差异.
相关概念视频
Exercise and Cardiovascular Response
797
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
797
Oral Hypoglycemic Agents: Biguanides and Glitazones
195
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195


